273 related articles for article (PubMed ID: 28121742)
1. Association of Baseline Viral Serology and Sirolimus Regimens With Kidney Transplant Outcomes: A 14-Year Registry-Based Cohort Study in the United States.
Santos AH; Casey MJ; Xuerong W; Womer KL
Transplantation; 2017 Feb; 101(2):377-386. PubMed ID: 28121742
[TBL] [Abstract][Full Text] [Related]
2. New-onset diabetes after kidney transplantation: can the risk be modified by choosing immunosuppression regimen based on pretransplant viral serology?
Santos AH; Chen C; Casey MJ; Womer KL; Wen X
Nephrol Dial Transplant; 2018 Jan; 33(1):177-184. PubMed ID: 29045704
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of sirolimus regimens in 65-year-old and older kidney transplant recipients: a registry-based observational study.
Santos AH; Chen C; Alquadan K; Wen X
Int Urol Nephrol; 2019 Nov; 51(11):2063-2072. PubMed ID: 31385180
[TBL] [Abstract][Full Text] [Related]
4. Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era.
Gralla J; Wiseman AC
Transplantation; 2009 Jun; 87(11):1712-9. PubMed ID: 19502965
[TBL] [Abstract][Full Text] [Related]
5. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
de Sandes-Freitas TV; Felipe CR; Campos ÉF; de Lima MG; Soares MF; de Franco MF; Aguiar WF; Tedesco-Silva H; Medina-Pestana JO
Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
[TBL] [Abstract][Full Text] [Related]
6. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database.
Watt KD; Dierkhising R; Heimbach JK; Charlton MR
Liver Transpl; 2012 Sep; 18(9):1029-36. PubMed ID: 22641474
[TBL] [Abstract][Full Text] [Related]
7. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
[TBL] [Abstract][Full Text] [Related]
8. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus.
Meier-Kriesche HU; Schold JD; Srinivas TR; Howard RJ; Fujita S; Kaplan B
Am J Transplant; 2005 Sep; 5(9):2273-80. PubMed ID: 16095509
[TBL] [Abstract][Full Text] [Related]
10. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
11. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
[TBL] [Abstract][Full Text] [Related]
12. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
13. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
14. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
[TBL] [Abstract][Full Text] [Related]
15. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
Pliszczynski J; Kahan BD
Transplant Proc; 2011 Dec; 43(10):3657-68. PubMed ID: 22172822
[TBL] [Abstract][Full Text] [Related]
16. Incidence, Risk Factors and Outcomes of Delayed-onset Cytomegalovirus Disease in a Large Retrospective Cohort of Lung Transplant Recipients.
Santos CA; Brennan DC; Yusen RD; Olsen MA
Transplantation; 2015 Aug; 99(8):1658-66. PubMed ID: 25675196
[TBL] [Abstract][Full Text] [Related]
17. The use of sirolimus in patients with recurrent cytomegalovirus infection after kidney transplantation: A retrospective case series analysis.
Shendi AM; Hung RKY; Caplin B; Griffiths P; Harber M
Saudi J Kidney Dis Transpl; 2019; 30(3):606-614. PubMed ID: 31249224
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation.
Srinivas TR; Schold JD; Guerra G; Eagan A; Bucci CM; Meier-Kriesche HU
Am J Transplant; 2007 Mar; 7(3):586-94. PubMed ID: 17229066
[TBL] [Abstract][Full Text] [Related]
19. Prospective observational study of sirolimus as primary immunosuppression after renal transplantation.
Pescovitz MD; Nezakatgoo N; Lorber MI; Nashan B; Tedesco-Silva H; Kasiske BL; de la Cruz FJ; Russ G; Campistol J; Keown PA;
Transplantation; 2009 Oct; 88(8):1010-8. PubMed ID: 19855247
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus-associated smooth muscle tumors after kidney transplantation: treatment and outcomes in a single center.
Tan CS; Loh HL; Foo MW; Choong LH; Wong KS; Kee TY
Clin Transplant; 2013; 27(4):E462-8. PubMed ID: 23682851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
